Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 6, September, p. 999–1004

doi: 10.17219/acem/63031

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Differences in echocardiography, blood pressure, stroke volume, maximal power and profile of genes related to cardiac hypertrophy in elite road cyclists

Grażyna Janikowska1,A,B,C,D,E,F, Aleksandra Żebrowska2,A,B,C,D,E,F, Aleksandra Kochańska-Dziurowicz3,4,B,C,E,F, Urszula Mazurek5,C,F

1 Department of Analytical Chemistry, Medical University of Silesia, Katowice, Poland

2 Department of Physiology, The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland

3 Department of Isotope Diagnostic and Radiopharmacy, Medical University of Silesia, Katowice, Poland

4 Department of Health Care, Silesian Medical College, Katowice, Poland

5 Department of Molecular Biology, Medical University of Silesia, Katowice, Poland

Abstract

Background. Regular and moderate exercise is beneficial for improving the efficiency of the heart, but high-intensity physical activity may result in cardiac changes.
Objectives. This study focuses on the identification of the differences in echocardiography and blood variables before exercise, as well as the genes associated with cardiac hypertrophy at rest and in response to graded exercise test.
Material and Methods. The study group was made up of 28 road cyclists. Echocardiographic parameters and blood pressure were measured before exercise tests (N = 28). Blood samples were collected at rest, at maximal exercise intensity in a graded bicycle test and after 15 min of recovery; afterwards, blood morphology was estimated and RNA was isolated. Analysis of the expression profile of genes was performed for randomly selected road cyclists using the microarray method.
Results. Echocardiographic results and blood parameters divided cyclists into two groups: with and without left ventricular hypertrophy (N = 14). Differences in the structure and function of the left ventricle cyclists with a similar level of training were observed (p < 0.05). Diastolic blood pressure and resting heart rate were significantly lower in subjects with left ventricular hypertrophy (p < 0.05). The myosin light chain 9 and interleukin-6 signal transducer gene expression were differentially regulated in cyclists with left ventricular hypertrophy compared to athletes with normal heart dimensions in response to intensive exercise.
Conclusion. We have found differences in echocardiography parameters, blood pressure, stroke volume and maximal power in the cyclists examined. These studies indicate the benefits of the recommended echocardiography measurements for professional endurance-athletes. The graded exercise altered the myosin light chain 9 and interleukin-6 signal transducer gene expression in the peripheral blood of road cyclists has also been found.

Key words

gene expression, exercise, echocardiography, left ventricular hypertrophy, road cyclists

References (30)

  1. Lavie CJ, Arena R, Swift DL, et al. Exercise and the cardiovascular system: Clinical science and cardiovascular outcomes. Circ Res. 2015;117:207–219.
  2. Thiene G, Corrado D, Rigato I, Basso C. Why and how to support screening strategies to prevent sudden death in athletes. Cell Tissue Res. 2012;348:315–318.
  3. Oxborough D, Sharma S, Shave R, et al. The right ventricle of the endurance athlete: The relationship between morphology and deformation. J Am Soc Echocardiogr. 2012;25:263–271.
  4. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiograpgy and the European Association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2015;16:233–270.
  5. Leischik R, Spelberg N. Endurance sport and cardiac injury: Prospective study of recreational ironman athletes. Int J Environ Res Public Health 2014;11:9082–9100.
  6. Pelliccia A, Maron MS, Maron BJ. Assessment of left ventricular hypertrophy in a trained athlete: Differential diagnosis of physiologic athlete’s heart from pathologic hypertrophy. Prog Cardiovasc. Dis 2012;54:387–396.
  7. Pavlik G, Major Z, Csajagi E, Jeserich M, Kneffel Z. The athlete’s heart. Part II. Influencing factors on the athlete’s heart: Types of sports and age. Acta Physiol Hung. 2013;100:1–27.
  8. Neri Serneri GC, Boddi M, Modesti PA, et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circulation Res. 2001;89:977–982.
  9. Gielen S, Schuler G, Adams V. Cardiovascular effects of exercise training molecular mechanisms. Circulation. 2010;101:1221–1238.
  10. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128:191–227.
  11. Baggish AL, Wood MJ. Athlete’s heart and cardiovascular care of the athlete: Scientific and clinical update. Circulation. 2011;123:2723–2735.
  12. Scott JM, Warburton DE. Mechanisms underpinning exercise-induced changes in left ventricular function. Med Sci Sports Exerc. 2008;40:1400–1407.
  13. Booth FW, Chakravarthy MV, Spangenburg EE. Exercise and gene expression: Physiological regulation of the human genome through physical activity. J Physiol. 2002;543:399–411.
  14. Strøm CC, Aplin M, Ploug T, et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J. 2005;272:2684–2695.
  15. Devereux RB, Alonso R, Lutas R, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450–458.
  16. Choe SE, Boutros M, Michelson AM, Church GM, Halfon MS. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 2005;6:R16.
  17. D’Andrea A, Caso P, Scarafile R, et al. Biventricular myocardial adaptation to different training protocols in competitive master athletes. Int J Cardiol. 2007;115:342–349.
  18. Shapiro LM. Physiological left ventricular hypertrophy. Br Heart J. 1984;52:130–135.
  19. Horowitz I, Cafri C, Zeller L, Vodonos A, Perry ZH, Kobal SL. Athlete’s heart in Israel: fact or fiction. Isr Med Assoc J. 2014;16:46–49.
  20. Moro AS, Okoshi MP, Padovani CR, Okoshi K. Doppler echocardiography in athletes from different sports. Med Sci Monit. 2013;19:187–193.
  21. Shehadeh LA, Webster KA, Hare JM, Vazquez-Padron RI. Dynamic regulation of vascular myosin light chain (MYL9) with injury and aging. PLoS One. 2011;6:e25855.
  22. Jalagadugula G, Mao G, Kaur G, Goldfinger LE, Dhanasekaran DN, Rao AK. Regulation of platelet myosin light chain (MYL9) by RUNX1: Implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency. Blood. 2010;116:6037–6045.
  23. Kaneko-Kawano T, Takasu F, Naoki H, et al. Dynamic regulation of myosin light chain phosphorylation by Rho-kinase. PLoS One. 2012;7:e39269.
  24. Lauschke J, Maisch B. Athlete’s heart or hypertrophic cardiomyopathy? Clin Res Cardiol. 2009;98:80–88.
  25. Iemitsu M, Maeda S, Miyauchi T, Matsuda M, Tanaka H. Gene expression profiling of exercise-induced cardiac hypertrophy in rats. Acta Physiol Scand. 2005;185:259–270.
  26. Jin H, Yang R, Li W, et al. Effects of exercise training on cardiac function, gene expression, and apoptosis in rats. Am J Physiol Heart Circ Physiol. 2000;279:H2994–H3002.
  27. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97:189−198.
  28. Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol. 2008;153:S414−S427.
  29. Wollert KC, Taga T, Saito M, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy: Assembly of sarcomeric units in series IA p130/leukemia inhibitory factor receptor dependent pathways. J Biol Chem. 1996;271:9535–9545.
  30. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol. 2006;57:43–51.
© Wroclaw Medical University